The Eagle Bioscience’s Anti-Beta2 Glycoprotein 1 IgG ELISA was recently highlighted in a publication on the effects of hydroxychloroquine onantiphospholipid antibodies-inhibited endometrial angiogenesis. Check out the abstract and full-text article below.
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by thrombotic events and/or pregnancy morbidity (≥3 recurrent early miscarriage or fetal death or a prematurity <34 weeks of gestation) with persistently positive antiphospholipid antibodies (aPLs). It is reported that aPLs damage the placental tissue by binding to β2-glycoprotein I (β2GPI) on the surface of trophoblast and endothelial cells. Hydroxychloroquine (HCQ) is considered to be beneficial in the treatment of obstetrical APS and shown to restore the aPL-inhibited invasion and differentiation of trophoblast. However, not enough evidence exists regarding the effect of HCQ on endometrial angiogenesis. The aim of our study was to assess whether HCQ has an effect on aPL-inhibited endothelial angiogenesis. In this research, to explore the effect of HCQ for angiogenesis, we investigated: Human umbilical vein endothelial cells (HUVECs) viability by CCK-8; HUVECs migration by wound healing; HUVEC angiogenesis by Matrigel assay in vitro; mRNA expression of MMP-2 and VEGF by real-time quantitative Polymerase Chain Reaction (RT-PCR); protein expression of VEGF, MMP-2 by western blot. We found that HCQ treatment significantly restored the expression of aPL-inhibited VEGF and MMP-2. HCQ restored aPL-inhibited HUVEC proliferation, migration, and angiogenesis in vitro. In conclusion, aPLs inhibit HUVECs angiogenesis, however, HCQ can restore the effect of aPL-inhibited HUVECs migration and angiogenesis in vitro, demonstrating its beneficial therapeutic role in obstetrical APS.